Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

  • Moran, Sebastian
  • Martínez Cardús, Anna
  • Sayols, Sergi
  • Musulén, Eva
  • Balañá, Carme
  • Estival Gonzalez, Anna
  • Moutinho, Cátia
  • Heyn, Holger
  • Diaz-Lagares, Ángel
  • Castro de Moura, Manuel
  • Stella, Giulia M.
  • Comoglio, Paolo M.
  • Ruiz Miró, Maria
  • Pazo Cid, Roberto
  • Antón, Antonio
  • Lopez Lopez, Rafael
  • Soler, Gemma
  • Longo, Federico
  • Guerra, Isabel
  • Fernandez, Sara
  • Assenov, Yassen
  • Plass, Christoph
  • Morales, Rafael
  • Carles, Joan
  • Bowtell, David
  • Mileshkin, Linda
  • Sia, Daniela
  • Tothill, Richard
  • Tabernero, Josep
  • Llovet, Josep M.
  • Esteller, Manel
  • Matias-Guiu, Xavier
Cancer of unknown primary ranks in the top ten cancer presentations and has an extremely poor prognosis. Identification of the primary tumour and development of a tailored site-specific therapy could improve the survival of these patients. We examined the feasability of using DNA methylation profiles to determine the occult original cancer in cases of cancer of unknown primary., The research leading to these results has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme by the ERC Proof-of-Concept Grant EPICUP, under grant agreement No 640696 (to ME); the Cellex Foundation (to ME); the Institute of Health Carlos III (ISCIII) under the Integrated Project of Excellence number PIE13/00022 (ONCOPROFILE); Cancer Research Australia APP1048193 and AP1082604 and Victorian Cancer Agency TRP13062 (to DB, LM, and RT); the Samuel Waxman Foundation (to JML); the Health and Science Deapartments of the Generalitat de Catalunya (to JML and ME); and Ferrer (to ME).
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences

  • Moran, Sebastian
  • Arribas, Carles
  • Esteller, Manel, 1968-
DNA methylation is the best known epigenetic mark. Cancer and other pathologies show an altered DNA methylome. However, delivering complete DNA methylation maps is compromised by the price and labor-intensive interpretation of single nucleotide methods. MATERIAL & METHODS: Following the success of the HumanMethylation450 BeadChip (Infinium) methylation microarray (450K), we report the technical and biological validation of the newly developed MethylationEPIC BeadChip (Infinium) microarray that covers over 850,000 CpG methylation sites (850K). The 850K microarray contains >90% of the 450K sites, but adds 333,265 CpGs located in enhancer regions identified by the ENCODE and FANTOM5 projects. RESULTS & CONCLUSION: The 850K array demonstrates high reproducibility at the 450K CpG sites, is consistent among technical replicates, is reliable in the matched study of fresh frozen versus formalin-fixed paraffin-embeded samples and is also useful for 5-hydroxymethylcytosine. These results highlight the value of the MethylationEPIC BeadChip as a useful tool for the analysis of the DNA methylation profile of the human genome.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

  • Moran, Sebastian
  • Martínez Cardús, Anna
  • Sayols, Sergi
  • Musulén, Eva
  • Balañá, Carme
  • Estival Gonzalez, Anna
  • Moutinho, Cátia
  • Heyn, Holger
  • Diaz-Lagares, Ángel
  • Castro de Moura, Manuel
  • Stella, Giulia M.
  • Comoglio, Paolo M.
  • Ruiz Miró, Maria
  • Pazo Cid, Roberto
  • Antón, Antonio
  • Lopez Lopez, Rafael
  • Soler, Gemma
  • Longo, Federico
  • Guerra, Isabel
  • Fernandez, Sara
  • Assenov, Yassen
  • Plass, Christoph
  • Morales, Rafael
  • Carles, Joan
  • Bowtell, David
  • Mileshkin, Linda
  • Sia, Daniela
  • Tothill, Richard
  • Tabernero, Josep
  • Llovet, Josep M.
  • Esteller, Manel
  • Matias-Guiu, Xavier
Cancer of unknown primary ranks in the top ten cancer presentations and has an extremely poor prognosis. Identification of the primary tumour and development of a tailored site-specific therapy could improve the survival of these patients. We examined the feasability of using DNA methylation profiles to determine the occult original cancer in cases of cancer of unknown primary., The research leading to these results has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme by the ERC Proof-of-Concept Grant EPICUP, under grant agreement No 640696 (to ME); the Cellex Foundation (to ME); the Institute of Health Carlos III (ISCIII) under the Integrated Project of Excellence number PIE13/00022 (ONCOPROFILE); Cancer Research Australia APP1048193 and AP1082604 and Victorian Cancer Agency TRP13062 (to DB, LM, and RT); the Samuel Waxman Foundation (to JML); the Health and Science Deapartments of the Generalitat de Catalunya (to JML and ME); and Ferrer (to ME).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences

  • Moran, Sebastian
  • Arribas, Carles
  • Esteller, Manel
DNA methylation is the best known epigenetic mark. Cancer and other pathologies show an altered DNA methylome. However, delivering complete DNA methylation maps is compromised by the price and labor-intensive interpretation of single nucleotide methods. MATERIAL & METHODS: Following the success of the HumanMethylation450 BeadChip (Infinium) methylation microarray (450K), we report the technical and biological validation of the newly developed MethylationEPIC BeadChip (Infinium) microarray that covers over 850,000 CpG methylation sites (850K). The 850K microarray contains >90% of the 450K sites, but adds 333,265 CpGs located in enhancer regions identified by the ENCODE and FANTOM5 projects. RESULTS & CONCLUSION: The 850K array demonstrates high reproducibility at the 450K CpG sites, is consistent among technical replicates, is reliable in the matched study of fresh frozen versus formalin-fixed paraffin-embeded samples and is also useful for 5-hydroxymethylcytosine. These results highlight the value of the MethylationEPIC BeadChip as a useful tool for the analysis of the DNA methylation profile of the human genome.